All In Biotech

Drug Trial Radar · NCT03580044

Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria

A PROSPECTIVE, RANDOMIZED,OPEN-LABEL, COMPARATIVE STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF AZTREONAM- AVIBACTAM (ATM-AVI) AND BEST AVAILABLE THERAPY FOR THE TREATMENT OF SERIOUS INFECTIONS DUE TO MULTI-DRUG RESISTANT GRAM- NEGATIVE BACTERIA PRODUCING METALLO -Β-LACTAMASE (MBL)

Last checked: Nov 20, 2026Latest source record: Feb 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

15

Actual

Start

Dec 25, 2020

Primary completion

Jan 23, 2023

Study completion Jan 23, 2023

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
Collaborators
Allergan
First posted
Jul 9, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 3 study to determine the efficacy, safety, and tolerability of aztreonam- avibactam (ATM- AVI) versus best available therapy (BAT) in the treatment of hospitalized adults with complicated intra-abdominal infections (cIAI), nosocomial pneumonia (NP) including hospital acquired pneumonia (HAP) and ventilator associated pneumonia (VAP), complicated urinary tract infections (cUTI), or bloodstream infections (BSI) due to metallo-β-lactamase (MBL)- producing Gram-negative bacteria.

Conditions

  • Serious Bacterial Infection

Interventions

  • ATM-AVICombination product

    ATM-AVI doses (loading, extended loading and maintenance) and the dosing frequency of the maintenance dose are dependent on renal function. Subjects will be given a loading dose of 500 mg ATM plus 167 mg AVI or 675 mg ATM plus 225 mg AVI over a period of 30 minutes. This treatment will immediately be followed by an extended loading dose of 1500 mg ATM plus 500 mg AVI or 675 mg ATM plus 225 mg AVI over a period of 3 hours. Then there will be a 3 hour or 5 hour gap. Subjects will receive a maintenance dose of 1500 mg ATM plus 500 mg AVI every 6 hours or 750 mg ATM plus 250 mg AVI every 6 hours, or 675 mg ATM plus 225 mg AVI every 8 hours. Subjects with cIAI will also receive Metronidazole (MTZ) 500 mg IV q8h over 60 minutes. The first dose of MTZ will be started immediately after the extended loading dose of ATM-AVI has completed and treatment will be continued until the end of the treatment period.

  • BATDrug

    The comparator treatment in this study is best available therapy (BAT) based upon site practice and local epidemiology. The choice of BAT (monotherapy or combination) for each subject must be recorded prior to randomization. If the chosen BAT does not provide adequate anaerobic coverage for cIAI subjects MTZ is to be administered as a co therapy. BAT dose, frequency, dose adjustments with renal impairment will be based on per local package inserts.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Clinical Cure at the Test of Cure (TOC) Visit -Microbiological Intent to Treat (Micro-ITT) Analysis SetTime frame: Day 28

Locations

42 sites in 12 countries. Site status is shown where the registry gives one.

  • Banner University Medical Center Tucson

    Tucson, Arizona

  • Hospital San Roque

    Córdoba, Argentina

  • The First Hospital of Kunming

    Kunming, China

  • The First Affiliated Hospital of Shantou University Medical College

    Shantou, Guangdong, China

  • Hunan Province People's Hospital

    Changsha, Hunan, China

  • Baotou Central Hospital

    Baotou, Inner Mongolia, China

  • Huashan Hospital Fudan University

    Shanghai, Shanghai Municipality, China

  • The First Hospital of Kunming

    Kunming, Yunnan, China

  • General Hospital of Athens "Evangelismos"

    Athens, Greece

  • General and Chest Diseases Hospital "Sotiria"

    Athens, Greece

  • General Hospital of Athens "Laiko",

    Athens, Greece

  • University General Hospital "ATTIKON", Medicine and Infectious Diseases

    Athens, Greece

  • University General Hospital of Heraklion

    Heraklion, Crete, Greece

  • University General Hospital of Larissa

    Larissa, Greece

  • Victoria Hospital, Bangalore Medical College and Research Institute

    Bangalore, India

  • Government medical College

    Kozhikode, Kerala, India

  • Deenanath Mangeshkar Hospital And Research Centre

    Pune, Maharashtra, India

  • S.R.Kalla Memorial Gastro & General Hospital

    Jaipur, Rajasthan, India

  • Apollo Hospitals Enterprise Limited

    Chennai, Tamil Nadu, India

  • University Malaya Medical Centre

    Kuala Lumpur, Malaysia

  • Hospital Kuala Lumpur

    Kuala Lumpur, Kuala Lumpur, Malaysia

  • Hospital Civil de Guadalajara "Fray Antonio Alcalde"

    Guadalajara, Jalisco, Mexico

  • Davao Doctors Hospital

    Davao City, Philippines

  • Makati Medical Center

    Makati City, Philippines

  • Manila Doctors Hospital

    Manila, Philippines

  • St. Luke's Medical Center

    Quezon City, Philippines

  • Institutul National de Boli Infectioase "Prof. Dr. Matei Bals"

    Bucharest, Romania

  • Spitalul Clinic de Boli Infectioase si Tropicale "Dr. Victor Babes"

    Bucharest, Romania

  • Spitalul Clinic de Boli Infectioase Cluj Napoca

    Cluj-Napoca, Romania

  • Spitalul Clinic de Boli Infectioase "Sf. Parascheva" Iasi

    Iași, Romania

  • Spitalul Clinic Judetean de Urgenta "Pius Brinzeu"

    Timișoara, Romania

  • SBHI of the city of Moscow "N.I.Pirogov City Clinical Hospital # 1"

    Moscow, Russia

  • OGBUZ "Smolensk Regional Clinical Hospital"

    Smolensk, Russia

  • FSBEI of HE "Smolensk State Medical University" of the Ministry of Health of the RF

    Smolensk, Russia

  • SRI of Antimicrobial Chemotherapy

    Smolensk, Russia

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Kaohsiung City, Taiwan

  • Kaohsiung Veterans General Hospital

    Kaohsiung City, Taiwan

  • National Taiwan University Hospital

    Taipei, Taiwan

  • Faculty of Medicine Siriraj Hospital

    Bangkoknoi, Bangkok, Thailand

  • Bamrasnaradura Infectious Disease Institute (BIDI)

    Muang, Changwat Nonthaburi, Thailand

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.